# Functional Foods in Health Promotion and Disease Prevention: Innovations, Evidence and Challenges

**Authors:** Zheng Feei Ma, Shuchang Liu, Caili Fu, Shaobo Zhou, Yeong Yeh Lee

PMC · DOI: 10.3390/foods15040764 · Foods · 2026-02-19

## TL;DR

This review explores how functional foods can help prevent diseases like diabetes and heart disease, while addressing challenges in translating scientific evidence into real health benefits.

## Contribution

The paper provides a comprehensive review of functional foods, integrating evidence on bioactive compounds, consumer behavior, and regulatory frameworks across different regions.

## Key findings

- Bioactive compounds like polyphenols and probiotics show promise in promoting health but face challenges in bioavailability and individual variability.
- Consumer acceptance of functional foods is influenced by factors such as product format, health motivation, and price sensitivity.
- Regulatory frameworks for functional foods vary significantly between countries like the US, EU, Japan, and China.

## Abstract

Functional foods have attracted increasing scientific and commercial interest due to their potential roles in health promotion and the prevention of non-communicable diseases such as diabetes and cardiovascular diseases. In this review, we will critically examine the current evidence on functional foods by focusing on their classification, bioactive components, biological mechanisms, consumer acceptance and regulatory frameworks. Bioactive compounds, such as polyphenols, dietary fibre and probiotics, from both plant- and animal-origin functional foods, have also been examined in this review. Despite substantial experimental and epidemiological evidence, the translation of functional foods into consistent health benefits remains challenged by variability in bioavailability, food matrix effects, processing conditions and interindividual differences in genetics and gut microbiota. Key mechanistic determinants of bioefficacy, including intestinal transport processes, molecular structure, stereochemistry, and food–drug interactions, are discussed. Consumers’ perception and purchasing behaviour are examined, identifying the influence of product format, socio-demographic characteristics, information sources, health motivation and price sensitivity. Our review also compares the regulatory approaches in the United States, European Union, Japan and China, highlighting the heterogeneity in definitions and health claim substantiation requirements. Finally, emerging opportunities such as metabolic profiling technologies and personalised nutrition are highlighted as future directions to support evidence-based, effective and equitable functional food development.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** UGT1A4 (UDP glucuronosyltransferase family 1 member A4) [NCBI Gene 54657] {aka HUG-BR2, UDPGT 1-4, UGT-1D, UGT1-04, UGT1.4, UGT1A4S}, PPIG (peptidylprolyl isomerase G) [NCBI Gene 9360] {aka CARS-Cyp, CYP, SCAF10, SRCyp}, CYP4F3 (cytochrome P450 family 4 subfamily F member 3) [NCBI Gene 4051] {aka CPF3, CYP4F, CYPIVF3, LTB4H}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}, COMT (catechol-O-methyltransferase) [NCBI Gene 1312] {aka HEL-S-98n}, SLC22A6 (solute carrier family 22 member 6) [NCBI Gene 9356] {aka HOAT1, OAT1, PAHT, ROAT1}, ABCB6 (ATP binding cassette subfamily B member 6 (LAN blood group)) [NCBI Gene 10058] {aka ABC, LAN, MTABC3, PRP, umat}, LCT (lactase) [NCBI Gene 3938] {aka LAC, LPH, LPH1}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}, ABCG2 (ATP binding cassette subfamily G member 2 (JR blood group)) [NCBI Gene 9429] {aka ABC15, ABCP, BCRP, BMDP, CD338, CDw338}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}
- **Diseases:** diabetes (MESH:D003920), cancer (MESH:D009369), injury to (MESH:D014947), inflammatory (MESH:D007249), non-communicable diseases (MESH:D000073296), obesity (MESH:D009765), osteoporosis (MESH:D010024), age- (MESH:D019588), toxicity (MESH:D064420), cardiovascular death (MESH:D002318), Hypertriglyceridemia (MESH:D015228), Chronic diseases (MESH:D002908)
- **Chemicals:** beta-lactam antibiotics (MESH:D008997), plant sterols (MESH:D010840), quercetin glycosides (MESH:D012431), omega-3 fatty acids (MESH:D015525), dietary fibre (MESH:D004043), sugar (MESH:D000073893), salt (MESH:D012492), sesamin (MESH:C054125), fat (MESH:D005223), cholesterol (MESH:D002784), aglycone (MESH:C458179), (+)-catechin (MESH:D002392), carotenoid (MESH:D002338), lycopene (MESH:D000077276), phospholipids (MESH:D010743), EPA (MESH:D015118), selenium (MESH:D012643), lutein (MESH:D014975), proanthocyanidins (MESH:D044945), amino acids (MESH:D000596), isoflavones (MESH:D007529), lignan (MESH:D017705), hesperetin-7-glucoside (MESH:C545247), gamma-tocopherol (MESH:D024504), furanocoumarin (MESH:D011564), (R/S) isomers of equol (-), margarines (MESH:D008383), beta-glucan (MESH:D047071), calcium (MESH:D002118), folate (MESH:D005492), Icosapent Ethyl (MESH:C035276), Flavonoids (MESH:D005419), ellagic acid (MESH:D004610), sterol (MESH:D013261), alpha-tocopherol (MESH:D024502), DHA (MESH:D004281), lipid (MESH:D008055), bergamottin (MESH:C068337), polyphenols (MESH:D059808)
- **Species:** Lacticaseibacillus rhamnosus GG (strain) [taxon 568703], Agaricus bisporus (common mushroom, species) [taxon 5341], Lactobacillus acidophilus (species) [taxon 1579], Homo sapiens (human, species) [taxon 9606], Sesamum indicum (beniseed, species) [taxon 4182], Limosilactobacillus reuteri (species) [taxon 1598]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941354/full.md

## References

97 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941354/full.md

---
Source: https://tomesphere.com/paper/PMC12941354